scholarly journals Macular Amyloidosis and Epstein-Barr Virus

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Yalda Nahidi ◽  
Naser Tayyebi Meibodi ◽  
Zahra Meshkat ◽  
Narges Nazeri
Keyword(s):  
Epstein Barr Virus ◽  
Globin Gene ◽  
Control Group ◽  
Barr Virus ◽  
Significant Difference ◽  
Macular Amyloidosis ◽  
Ebv Dna ◽  
Epstein Barr ◽  
And Control ◽  
Skin Samples

Background. Amyloidosis is extracellular precipitation of eosinophilic hyaline material of self-origin with special staining features and fibrillar ultrastructure. Macular amyloidosis is limited to the skin, and several factors have been proposed for its pathogenesis. Detection of Epstein-Barr virus (EBV) DNA in this lesion suggests that this virus can play a role in pathogenesis of this disease.Objective. EBV DNA detection was done on 30 skin samples with a diagnosis of macular amyloidosis and 31 healthy skin samples in the margin of removed melanocytic nevi by using PCR.Results. In patients positive for beta-globin gene in PCR, BLLF1 gene of EBV virus was positive in 23 patients (8 patients in case and 15 patients in the control group). There was no significant difference in presence of EBV DNA between macular amyloidosis (3.8%) and control (23.8%) groups (P=0.08).Conclusion. The findings of this study showed that EBV is not involved in pathogenesis of macular amyloidosis.

scholarly journals LMP-1 IMMUNOHISTOCHEMICAL DETECTION OF EPSTEIN - BARR VIRUS IN LYMPHOMA AMONG SUDANESE PATIENTS

2015 ◽  
Vol 3 (9) ◽  
pp. 63-69
Author(s):  
Ibrahim BakhitYousif ◽  
Yousif Mohammed Yousif ◽  
SideegAbd Elaziz Mohammed
Keyword(s):  
Epstein Barr Virus ◽  
Sufficient Evidence ◽  
Control Group ◽  
Barr Virus ◽  
Formalin Fixed Paraffin ◽  
Significant Difference ◽  
Formalin Fixed Paraffin Embedded ◽  
Epstein Barr ◽  
Lymphoma Study Group ◽  
And Control

Several studies have suggested a probable etiologic association between Epstein-Barr virus (EBV) and lymphoma; multiple EBV proteins can be expressed in infected lymphocytes, among which Latent membrane protein-1(LMP-1) is thought to be most important for malignant transformation, the aim of this study was to investigate the association of LMP-1 EBV in this tumors. This study was carried at the Radio Isotope Center Khartoum (RICK)- Khartoum state –Sudan from January 2015 to July 2015, it was retrospective and prospective,  the study include  ninety (90) Formalin –fixed paraffin embedded biopsies from which  seventy (70) of malignant lymphoma (study group)  and twenty (20) lymph node hyperplasia  (control group ). EBV was detected in (32%) (23/70), and (10%) (2/20) respectively, the (P.value =0.04), this result showed a significant difference between case and control groups, the, there is no statistically significant difference between the two lymphoma subtypes Hodgkin's and Non-Hodgkin`s the   (P.value= 0.333). There is sufficient evidence for the carcinogenicity of EBV in the causation of lymphoma in Sudan. This requires further evaluation to find out whether this positivity is due to co-infection or has a role in pathogenesis.

scholarly journals Prevalence of Epstein Barr Virus in biopsy specimens of nasopharyngeal carcinoma from Serbian patients

2014 ◽  
Vol 66 (2) ◽  
pp. 537-544 ◽  
Author(s):  
Ana Banko ◽  
Ivana Lazarevic ◽  
M. Folic ◽  
Maja Cupic ◽  
Tanja Jovanovic
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Biopsy Specimens ◽  
C Terminus ◽  
Geographical Regions ◽  
Significant Difference ◽  
Ebv Dna ◽  
Epstein Barr

The development of nasopharyngeal carcinoma (NPC) is the result of interaction between Epstein-Barr Virus (EBV) and many non-viral factors. The aims of this study were to determine the prevalence of EBV in NPC biopsies from Serbian patients and to investigate the correlation between EBV presence and demographic, anamnestic and clinical data. Ninety-three tissue blocks were included. For detection of EBV DNA, the C terminus of the LMP1 gene was amplified by nested-PCR. Twenty-eight biopsies were EBV-DNA-positive (30.1%), with a statistically significant difference in EBV DNA presence between geographical regions (p=0.02) and between the stages of tumor-node-metastasis (TNM) (p=0.02). A correlation was also found with the presence of EBV DNA and smoking (p=0.02). The correlation of EBV DNA presence, with or without smoking and the promising outcome of the disease was statistically significant (p=0.02; p=0.01). The EBV DNA findings from this study confirm the role of EBV in NPC carcinogenesis, and show the different distribution among TNM stages and correlation between the virus and outcome of disease.

scholarly journals HLA-Mismatched GPBSCs infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A observational study from a single center

2020 ◽  
Author(s):  
Yue Song ◽  
Jingshi Wang ◽  
Yini Wang ◽  
Zhao Wang
Keyword(s):  
Survival Rate ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Median Survival Time ◽  
Epstein Barr Virus ◽  
Control Group ◽  
Short Term ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Better Than

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory state. Epstein–Barr virus (EBV) infection associated HLH (EBV-HLH) is one of the most common secondary HLH and suffers a very poor prognosis. Allo-HSCT is often required for refractory EBV-HLH, but some patients still cannot proceed to the next allo-HSCT due to various factors. This study aimed to observe the efficacy of HLA-mismatched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (GPBSCs) infusion for refractory EBV-HLH. Methods: A retrospective case-control study of refractory EBV-HLH patients with GPBSCs infusion from HLA-mismatched donors after chemotherapy (as GPBSCs group) and sole chemotherapy (as control group) was performed. Efficacy was evaluated 2 and 4 weeks and all patients were followed up until 1 March 2018.Results: There were 18 cases who accepted infusion between March 2016 and Sep 2017 and 19 were randomly selected from refractory EBV-HLH patients who underwent salvage therapy during the same period for the control group. In GPBSCs group, WBC (p=0.017), Fbg (p=0.040), ferritin (p=0.039) improved significantly after treatment. The overall response rate was 66.7% (CR 22.2%, PR 44.4%). However, there is no significant differences in changes of WBC, HGB, PLT, TG, Fbg, Ferritin, AST, ALT, T-bil between two groups. Only the Fbg level was recovered better in the GPBSCs infusion group (p=0.003). In the GPBSCs group, EBV-DNA decreased significantly after 2 weeks (p=0.001) and 4 weeks (p=0.012) after treatment, and the effect of the decrease was significantly better than that of the chemotherapy alone group in 2 weeks but not 4 weeks (p2w=0.011, p4w=0.145). The median survival time in the infusion group was 20.4 weeks [95%CI 10.9, 29.9], and the median survival time in the control group was 10.8 weeks [95%CI 0-24.34]. In the short-term, the infusion group’s survival rate was better (2-month 88.89% vs. 52.63%, p=0.008; 3-month 83.33% vs. 47.09%, p=0.012), but there was no difference in OS (p=0.287). Conclusions: Infusing GPBSCs combined with chemotherapy is effective, especially in decreasing EBV-DNA, performs better than chemotherapy alone, and improve short term survival rate. GPBSCs infusion is suggested as a bridging treatment method to allo-HSCT.

scholarly journals HLA-Mismatched GPBSCs infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A observational study from a single center

2020 ◽  
Author(s):  
Yue Song ◽  
Jingshi Wang ◽  
Yini Wang ◽  
Zhao Wang
Keyword(s):  
Survival Rate ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Median Survival Time ◽  
Epstein Barr Virus ◽  
Control Group ◽  
Short Term ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Better Than

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory state. Epstein–Barr virus (EBV) infection associated HLH (EBV-HLH) is one of the most common secondary HLH and suffers a very poor prognosis. Allo-HSCT is often required for refractory EBV-HLH, but some patients still cannot proceed to the next allo-HSCT due to various factors. This study aimed to observe the efficacy of HLA-mismatched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (GPBSCs) infusion for refractory EBV-HLH. Methods: A retrospective case-control study of refractory EBV-HLH patients with GPBSCs infusion from HLA-mismatched donors after chemotherapy (as GPBSCs group) and sole chemotherapy (as control group) was performed. Efficacy was evaluated 2 and 4 weeks and all patients were followed up until 1 March 2018. Results: There were 18 cases who accepted infusion between March 2016 and Sep 2017 and 19 were randomly selected from refractory EBV-HLH patients who underwent salvage therapy during the same period for the control group. In GPBSCs group, WBC (p=0.017), Fbg (p=0.040), ferritin (p=0.039) improved significantly after treatment. The overall response rate was 66.7% (CR 22.2%, PR 44.4%). However, there is no significant differences in changes of WBC, HGB, PLT, TG, Fbg, Ferritin, AST, ALT, T-bil between two groups. Only the Fbg level was recovered better in the GPBSCs infusion group (p=0.003). In the GPBSCs group, EBV-DNA decreased significantly after 2 weeks (p=0.001) and 4 weeks (p=0.012) after treatment, and the effect of the decrease was significantly better than that of the chemotherapy alone group in 2 weeks but not 4 weeks (p2w=0.011, p4w=0.145). The median survival time in the infusion group was 20.4 weeks [95%CI 10.9, 29.9], and the median survival time in the control group was 10.8 weeks [95%CI 0-24.34]. In the short-term, the infusion group’s survival rate was better (2-month 88.89% vs. 52.63%, p=0.008; 3-month 83.33% vs. 47.09%, p=0.012), but there was no difference in OS (p=0.287). Conclusions: Infusing GPBSCs combined with chemotherapy is effective, especially in decreasing EBV-DNA, performs better than chemotherapy alone, and improve short term survival rate. GPBSCs infusion is suggested as a bridging treatment method to allo-HSCT.

Demonstration of Epstein-Barr Virus DNA in Acetowhite Lesions of the Vulva

1994 ◽  
Vol 5 (1) ◽  
pp. 25-28 ◽  
Author(s):  
E Voog ◽  
A Ricksten ◽  
G B Löwhagen ◽  
A Ternesten
Keyword(s):  
Human Papilloma Virus ◽  
Epstein Barr Virus ◽  
Control Group ◽  
Papilloma Virus ◽  
Hpv Dna ◽  
Barr Virus ◽  
Oral Hairy Leukoplakia ◽  
Hairy Leukoplakia ◽  
Ebv Dna ◽  
Epstein Barr

Acetowhite lesions in the vulva disclosing koilocytosis have been related to infection by human papilloma virus (HPV). Because of the clinical resemblance of these lesions to oral hairy leukoplakia (OHL), and EBV-manifestation, 23 women with acetowhite koilocytotic lesions in the vulva were examined. The PCR-technique was used to detect EBV DNA as well as HPV DNA in 17% of 23 patients examined. In a control group of 19 patients EBV DNA was detected in 11% and HPV DNA in 42% of cell samples from normal vulvar mucosa. EBV DNA has not previously been demonstrated in the vulvar mucosa, and this virus might be related to subclinical acetowhite lesions.

scholarly journals Association of Epstein–Barr Virus and Cytomegalovirus Infections with Esophageal Carcinoma

2021 ◽  
Vol 14 (10) ◽  
Author(s):  
Mahin Ahangar Oskouee ◽  
Jamal Sarvari ◽  
Afagh Moattari ◽  
Ahmad Habibi ◽  
Amir Taher Eftehkar Sadat
Keyword(s):  
Esophageal Carcinoma ◽  
Epstein Barr Virus ◽  
Viral Infections ◽  
Control Group ◽  
Control Groups ◽  
Barr Virus ◽  
Potential Association ◽  
Epstein Barr ◽  
And Control ◽  
Cytomegalovirus Infections

Background: Given the fact that viral infections play an important role, either directly or indirectly, in around 20 percent of human cancers, this study aimed at investigating the potential association of Epstein–Barr virus (EBV) and cytomegalovirus (CMV) infections in esophageal cancer that is the sixth most common cause of cancer-related deaths. Methods: In this case-control study, a total of 200 paraffin-embedded biopsies of cancerous and benign esophageal tissues were gathered from the biopsy bank of Imam Reza Hospital, Tabriz, Iran in 2017. All samples were first deparaffinized, and then subjected to commercial DNA extraction. The quality of extracted DNA was evaluated by amplification of the beta globulin gene. Identification of EBV and CMV DNA was performed using primers designed for the EBER region of EBV and the immediate early (IE) region of the CMV genome, respectively. Results: The mean age of the subjects in the test and control groups was 52.2 (17.1) and 59.9 (18.9), respectively. The distribution of gender (male/female) in patient and control groups was 54/46 and 53/47, respectively. Our results showed that the frequency of EBV (P < 0.001) and CMV (P < 0.001) in cancerous samples was statistically higher than control group. Moreover, in the cancerous group the rate of EBV was significantly higher in the esophageal adenocarcinomas (EAC) sample (12 out of 70) than esophageal squamous cell carcinomas (ESCC) (0 out of 30) (P = 0.016) but, in the ESCC group, 17 out of 30 subjects were positive for CMV which was significantly higher in comparison with EAC patients (1 out of 70) (P < 0.001). Conclusions: Findings indicated that EBV and CMV might be contributed to the pathogenesis of EAC and ESCC types of esophageal carcinoma, respectively, although further studies are warranted.

scholarly journals Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin’s disease

2006 ◽  
Vol 124 (3) ◽  
pp. 154-157 ◽  
Author(s):  
Juliane Garcez Musacchio ◽  
Maria da Glória da Costa Carvalho ◽  
José Carlos Oliveira de Morais ◽  
Nathalie Henriques Silva ◽  
Adriana Scheliga ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Rio De Janeiro ◽  
Epstein Barr Virus ◽  
Advanced Disease ◽  
Hodgkin’S Disease ◽  
Hiv Positive ◽  
Control Group ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

CONTEXT AND OBJECTIVE: Free circulating Epstein-Barr virus (EBV) DNA is often present in the plasma of Hodgkin’s disease patients. The aim here was to evaluate the prevalence of this finding, its correlation with the immunohistochemical expression of LMP-1 (latent membrane protein 1) and the influence of other clinical factors. DESIGN AND SETTING: Prospective study in two public tertiary institutions: Hematology Service, Universidade Federal do Rio de Janeiro, and Oncology Service, Instituto Nacional do Câncer, Rio de Janeiro. METHODS: A cohort of 30 patients with newly diagnosed Hodgkin’s disease was studied. The control group consisted of 13 healthy adult volunteers. EBV DNA was determined by conventional polymerase chain reaction (PCR). RESULTS: The median age was 28 years, and 16 patients were women. Advanced disease was present in 19 patients, and six were HIV-positive. EBV DNA was present in the plasma of 13 patients and one control (43% versus 8%, p = 0.03). EBV DNA prevalence was higher in HIV-positive patients (100% versus 29%, p = 0.0007) and those with advanced disease (63% versus 9%, p = 0.006). Among HIV-negative patients alone, EBV DNA prevalence remained higher in those with advanced disease. EBV DNA was found in 10/11 patients with LMP-1 expression in the lymph nodes, and in 3/19 without LMP-1 expression (kappa coefficient = 0.72). CONCLUSION: EBV DNA was present in 91% of patients with EBV-associated Hodgkin’s disease, and in all patients with HIV-associated Hodgkin’s disease. EBV DNA prevalence was higher in patients with advanced disease, irrespective of HIV status.

Are acetowhite lesions of the cervix correlated to the presence of Epstein-Barr virus DNA?

1997 ◽  
Vol 8 (7) ◽  
pp. 432-436 ◽  
Author(s):  
Ewa Voog ◽  
Anne Ricksten ◽  
Monica Stenglein ◽  
Fredrik Jonassen ◽  
Annika Ternesten ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Predictive Factor ◽  
Epstein Barr Virus ◽  
Control Group ◽  
Study Group ◽  
Hpv Dna ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

The purpose of this study was to investigate whether Epstein-Barr virus (EBV) is associated with acetowhite lesions of the portio cervix, demonstrating koilocytosis and/or cervical intraepithelial neoplasia (CIN) I-III. The study group comprised 37 women admitted to the Department of Gynaecology and Obstetrics, Sahlgrenska University Hospital, Go teborg because of pathological colposcopy or cytology of the portio cervix. Colposcopically, all exhibited acetowhite lesions of the portio cervix. Cells were sampled with a cytobrush for examination for EBV and human papillomavirus (HPV) DNA by polymerase chain reaction (PCR) and a biopsy was taken for histopathology. Biopsies from 5 patients positive for EBV by PCR in cervical cell samples were examined by an in situ hybridization technique for EBER (Epstein-Barr virus encoded RNA), RNAs expressed in latent EBV infection. The control group consisted of women attending the Department of Dermato-Venereology at the same hospital for STD check-up. These had a normal cytology and no signs of acetowhiteness of the portio cervix. In the study group, EBV DNA was found in 30% and HPV DNA in 51%. In the control group 57% exhibited EBV DNA and 23% HPV DNA. EBV was not found to be a predictive factor in the development of koilocytosis and/or CIN I-III. HPV was a predictive factor in acetowhite, koilocytotic lesions. No expression of EBER was found in the 5 biopsies examined by in situ hybridization.

scholarly journals Association of subgingival Epstein–Barr virus and periodontitis

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 414
Author(s):  
Chaerita Maulani ◽  
Sri Lelyati C. Masulili ◽  
Widayat Djoko Santoso ◽  
Nurtami Soedarsono ◽  
Lindawati Kusdhany ◽  
...  
Keyword(s):  
Real Time ◽  
Real Time Pcr ◽  
Epstein Barr Virus ◽  
Gingival Crevicular Fluid ◽  
Barr Virus ◽  
Severe Periodontitis ◽  
Significant Difference ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Crevicular Fluid

Background: The Epstein–Barr virus (EBV) is gaining interest as a possible agent in the etiology of periodontitis. Previous studies have shown controversy on whether EBV DNA in the subgingival periodontal pockets is associated with periodontitis. The present study aimed to seek the potential relationship between EBV and periodontitis. Methods: Samples were taken from gingival crevicular fluid using sterile paper points, and data on sociodemographics, oral health, and periodontal health were recorded. This case-control study of 118 participants included 59 subjects with severe periodontitis and 59 control subjects with mild periodontitis. Quantitative real-time PCR was used to determined EBV load. Results: EBV DNA was detected in 37.3% of the case samples and 18.6% of the control samples. There was no significant difference in a load of EBV DNA between severe and mild periodontitis (p>0.05). The observed load of EBV DNA was up to 4.55x10 5 copies/mL. The detected EBV DNA was significantly associated with the plaque index and the oral hygiene index (p<0.05). Conclusions: Although no significant association was found, EBV may play a role in periodontitis. The real-time PCR methods can be used to monitor the EBV load in gingival crevicular fluid.

scholarly journals Molecular Detection of Epstein–Barr Virus, Human Herpes Virus 6, Cytomegalovirus, and Hepatitis B Virus in Patients with Multiple Sclerosis

2020 ◽  
Vol 12 (3) ◽  
pp. 171-177
Author(s):  
Mohsen Asouri ◽  
Mohammad Ali Sahraian ◽  
Morteza Karimpoor ◽  
Sadegh Fattahi ◽  
Nima Motamed ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Control Group ◽  
Case Group ◽  
Control Groups ◽  
Barr Virus ◽  
Human Herpes Virus ◽  
B Virus ◽  
Human Herpes Virus 6 ◽  
Epstein Barr ◽  
And Control

BACKGROUND Multiple sclerosis (MS) is a chronic disease with significant morbidity. A wide spectrum of risk factors has been suggested that triggers the development of MS. Among them, several viral infections have been implicated to play a role in MS pathogenesis. We aimed to evaluate the relationship between viral diseases, including Epstein–Barr virus (EBV), human herpes virus 6 (HHV-6), cytomegalovirus (CMV), and hepatitis B virus (HBV) and MS in the present case-control study. METHODS About 100 patients with confirmed MS and age- and sex-matched individuals were selected as case and control groups, respectively. The patients were randomly selected from individuals diagnosed by neurologists based on the clinical signs and symptoms and imaging procedures. RESULTS More than 100 patients with MS and patients who were referred for other causes were analyzed for the presence of DNA of EBV, HHV6, CMV, and HBV separately. 9.37% of the control group had a positive test for the DNA of EBV in a real-time polymerase chain reaction (PCR), while the frequency of positive test result was zero in the case group (p = 0.0012). HBV DNA was not detected in both the case and control groups. The prevalence of CMV was 0.88 and zero in the control and case groups, respectively (p = 0.3410). For HHV6, 9.73 % of the control group had a positive result, while this test was positive in 5.88% of the patients with MS (p = 0.2959). CONCLUSION We detected a significantly higher number of individuals with DNA of EBV in their blood among the control group compared with the case group. In conclusion, the results suggest a surprisingly adverse association between MS and EBV, and no association was found between the presence of DNA of HBV, CMV, and HHV6 and MS.

Sign in / Sign up

Export Citation Format

Share Document